Free Trial
NASDAQ:MNKD

MannKind Q3 2025 Earnings Report

MannKind logo
$4.88 -0.26 (-5.12%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$4.82 -0.06 (-1.19%)
As of 10/10/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind EPS Results

Actual EPS
N/A
Consensus EPS
$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

MannKind Revenue Results

Actual Revenue
N/A
Expected Revenue
$80.47 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MannKind Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

MannKind Earnings Headlines

MannKind Completes Acquisition of scPharma
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
See More MannKind Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MannKind? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MannKind and other key companies, straight to your email.

About MannKind

MannKind (NASDAQ:MNKD) is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S. Food and Drug Administration (FDA) approval in 2014 and is marketed directly by MannKind in the United States. The company initially entered into a co-promotion agreement with Sanofi for U.S. distribution of Afrezza, though that partnership concluded in 2016, prompting MannKind to establish its own commercial infrastructure. Beyond Afrezza, MannKind continues to evaluate additional indications for its Technosphere platform, including therapies for pulmonary hypertension and other conditions where rapid drug uptake via inhalation may offer clinical benefits.

Founded in 1991 by biomedical entrepreneur Dr. Alfred E. Mann, MannKind is headquartered in Westlake Village, California. Its leadership team includes President and Chief Executive Officer Michael Castagna, who has guided the company’s commercial operations and pipeline development since 2015. MannKind’s research and development activities are conducted primarily in the United States, with plans to seek regulatory approvals and partnerships in international markets as part of its long‐term growth strategy.

Through its focus on inhalation science and patient‐centric product design, MannKind aims to broaden the applications of its Technosphere technology beyond diabetes care. The company remains committed to advancing novel therapies that leverage the lung as a route of drug delivery, potentially transforming treatment paradigms for metabolic and respiratory diseases.

View MannKind Profile

More Earnings Resources from MarketBeat